J Drugs Dermatol. 2020 Nov 1;19(11):1076-1079. doi: 10.36849/JDD.2020.1012.
Device-based therapeutic approaches have been developed to treat women’s genitourinary post-menopausal symptoms. Fractional carbon dioxide laser resurfacing (FxCO2) has been demonstrated to be safe and effective in the treatment of GSM symptoms, however the results begin to wane by 12-months post-treatment.
This study aims at assessing the application of an at-home transvaginal red and infrared light device as a maintenance treatment commencing 12 months following FxCO2 laser treatment for genitourinary syndrome of menopause (GSM).
Subjects completing 12-month follow-up after three fractional CO2 laser vulvovaginal treatments received an at-home device and monitored for GSM symptoms with long-term follow-up to 12 months (2 years post-laser).
10 post-menopausal subjects completing 12-months follow-up after three FxCO2 vulvovaginal treatments for GSM were treated with an at-home red and infrared LED device. Treatment consisted of intravaginal application three times per week, and subjects were followed to 1, 3, 6, and 12 months. Subjects completed the vaginal assessment scale subject satisfaction, and QUID to assess for vulvovaginal and stress urinary incontinence (SUI) symptoms.
Vulvovaginal symptoms measured by VAS were mean 89% improved at 12-month follow-up after FxCO2 and maintained at 73% improved over baseline (2 years post-laser) following an additional 12 months of at-home transvaginal light therapy (P<0.05). VAS symptoms gradually increased over the 12 months maintenance period by a mean of 17% (P<0.05). Mean subject satisfaction was 0 at baseline, 1.86 at 1 year following FxCO2, and 1.00 after an additional 1 year of at-home light therapy. SUI symptoms as measured by QUID were mean 81% improved at 12-month follow-up after FxCO2and maintained at 38% improved over baseline (2 years post-laser) following an additional 12-months of at-home light therapy (P<0.05). SUI symptoms gradually increased by a mean of 43% over the 12-month maintenance period (P<0.05).
At-home transvaginal red and near infrared light therapy commencing at 12 months post-FxCO2 vulvovaginal treatment in a post-menopausal population maintained statistically significant improvements in vulvovaginal and SUI symptoms over the additional12-month period (2 years post-laser); however, a gradual return of symptoms suggests that laser re-treatment or combination withhormone therapy may be necessary to maintain optimal outcomes.J Drugs Dermatol. 2020;19(11):1076-1079. doi:10.36849/JDD.2020.1012.
已经开发出基于设备的治疗方法来治疗女性泌尿生殖系统绝经后症状。 分 段二氧化碳激光换肤术（FxCO2）已被证明可安全有效地治疗 GSM 症状，但治疗后 12 个月时效果开始减弱。
本研究旨在评估在家用经阴道红-红外光设备作为治疗绝经后女性泌尿生殖系统综合征（GSM）的 FxCO2 激光治疗后 12 个月的维持治疗中的应用。
完成三次 FxCO2 外阴阴道治疗后 12 个月随访的受试者接受家用设备治疗，并进行长期随访至 12 个月（激光治疗后 2 年），以监测 GSM 症状。
10 名完成三次 FxCO2 外阴阴道 GSM 治疗后 12 个月随访的绝经后女性受试者接受家用红-红外 LED 设备治疗。治疗包括每周阴道内应用 3 次，随访至 1、3、6 和 12 个月。受试者完成阴道评估量表（包括主观满意度和 QUID）以评估外阴阴道和压力性尿失禁（SUI）症状。
FxCO2 治疗后 12 个月时，VAS 测量的外阴阴道症状平均改善 89%，并在激光治疗后 12 个月（2 年）时基线水平上保持 73%的改善（激光治疗后 12 个月）。在另外 12 个月的家用经阴道光疗后，VAS 症状逐渐增加了 17%（P＜0.05）。受试者的平均满意度在基线时为 0，在 FxCO2 治疗后 1 年时为 1.86，在接受家用光疗后 1 年时为 1.00。FxCO2 治疗后 12 个月时，QUID 测量的 SUI 症状平均改善 81%，并在激光治疗后 12 个月（2 年）时基线水平上保持 38%的改善（激光治疗后 12 个月）。在另外 12 个月的家用光疗后，SUI 症状逐渐增加了 43%（P＜0.05）。
在绝经后人群中，在 FxCO2 外阴阴道治疗后 12 个月开始进行家用经阴道红-近红外光治疗，在另外 12 个月（激光治疗后 2 年）的治疗期间，在外阴阴道和 SUI 症状方面保持了统计学上显著的改善；然而，症状的逐渐恢复表明激光再治疗或与激素治疗联合可能是维持最佳治疗效果的必要手段。
皮肤病学杂志。2020;19（11）：1076-1079。doi：10.36849/JDD.2020.1012。
